Findings of a review analyzing the association between cigarette smoking and multiple sclerosis (MS) highlight numerous detrimental effects the habit has on those with the disease. The review, published in the Journal of the America Medical Association (JAMA) Neurology, collected data from studies published between 1965 and 2018.
Findings of a review analyzing the association between cigarette smoking and multiple sclerosis (MS) highlight numerous detrimental effects the habit has on those with the disease.
The review, published in the Journal of the America Medical Association (JAMA) Neurology, collected data from studies published between 1965 and 2018.
By taking the results of all the included studies into consideration researchers found, “patients with MS who smoke have higher rates of disease activity, faster rates of brain atrophy, and a greater disability burden.” Studies measured both the duration and intensity of the habit in patients with MS.
With over 2 billion consumers worldwide, and 5.8 trillion cigarettes consumed each year, risks associated with smoking cigarettes are experienced on a global level. Importantly, smoking cigarettes is more prevalent among patients with MS than the general population.
MS, which is a “chronic neurologic disorder characterized by demyelination and axonal loss in the central nervous system,” is often impacted by environmental factors, such as smoking. In addition to exacerbating the symptoms and ailments accompanying the disease, researchers found smoking cigarettes can limit the effectiveness of disease-modifying drugs.
Also, patients who smoke can see their MS progress more quickly. “Smoking has been shown to accelerate brain atrophy rates in the early disease stages, including in patients with clinically isolated syndrome (CIS),” the authors said. CIS is the earliest phase of MS.
Patients with MS tend to exhibit more comorbid disorders than the general population. Because smoking has severe implications on nearly every bodily system, comorbidities are exacerbated by the habit. “Smoking is implicated in the pathogenesis of other autoimmune disorders…patients with MS who smoked were more likely to develop another autoimmune disorder,” the authors said.
Despite the negative consequences, studies have found that patients with MS use smoking cigarettes as a coping mechanism. For this reason, patients often fail to quit. Unsuccessful attempts to quit smoking also lead to increased stress levels and have been associated with depression in patients with MS.
To combat the many negative impacts smoking has on patients with MS, researchers stress the importance of effective cessation mechanisms, one of which is counseling.
They state, “the increase in mortality rates appears to decrease after smoking cessation, which highlights the need for counseling…counseling is key in supporting patients before and during smoking cessation.”
The authors explain that physicians should expressly convey the benefits of quitting smoking to patients in a nonjudgmental manner and should be aware of the effect withdrawal may have on patients with MS.
Though the review focused specifically on the effects of smoking cigarettes on patients with MS, the authors suggest future studies look into associations between other detriments and the disease. One limitation present in multiple studies was the ambiguous definition of "passive smoking" adopted by researchers. This oversight led to discrepancies in findings. Future studies should also look into the associated consequences resulting from e-cigarette use.
“The pathway of MS pathogenesis in smokers may provide additional insights in the biologic factors associated with MS. Furthermore, the pathways involved in smoking may be implicated in other environmental exposures (e.g. organic solvents) and health habits (e.g. waterpipe smoking),” researchers concluded.
Reference
Rosso M, Chitnis T. Association between cigarette smoking and multiple sclerosis [published online December 16,2019]. JAMA Neurol. doi: 10.1001/jamaneurol.2019.4271.
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Upadacitinib Shows Promise for Hard-to-Treat Crohn Disease
April 23rd 2025Upadacitinib showed promising results in achieving clinical and endoscopic remission in people with moderate to severe Crohn disease, including those previously treated with advanced therapies, offering a potential second-line treatment option with a manageable safety profile.
Read More
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More